Wall Street brokerages forecast that Corium International Inc (NASDAQ:CORI) will post earnings per share (EPS) of ($0.33) for the current quarter, Zacks reports. Two analysts have provided estimates for Corium International’s earnings, with estimates ranging from ($0.36) to ($0.29). Corium International reported earnings per share of ($0.36) during the same quarter last year, which would indicate a positive year over year growth rate of 8.3%. The firm is scheduled to report its next quarterly earnings results on Thursday, November 15th.

According to Zacks, analysts expect that Corium International will report full year earnings of ($1.53) per share for the current financial year, with EPS estimates ranging from ($1.56) to ($1.50). For the next financial year, analysts forecast that the company will report earnings of ($1.42) per share, with EPS estimates ranging from ($1.73) to ($1.10). Zacks’ EPS averages are an average based on a survey of research analysts that cover Corium International.

Corium International (NASDAQ:CORI) last posted its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.04. The business had revenue of $7.67 million during the quarter, compared to the consensus estimate of $6.72 million. Corium International had a negative return on equity of 276.89% and a negative net margin of 155.21%.

A number of equities analysts have issued reports on the stock. BidaskClub cut shares of Corium International from a “sell” rating to a “strong sell” rating in a report on Saturday, September 15th. Zacks Investment Research raised shares of Corium International from a “sell” rating to a “hold” rating in a report on Tuesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Corium International in a report on Monday, August 13th. ValuEngine raised shares of Corium International from a “hold” rating to a “buy” rating in a report on Friday, August 10th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 target price on shares of Corium International in a report on Friday, August 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Corium International presently has a consensus rating of “Buy” and an average price target of $12.80.

NASDAQ:CORI traded up $0.36 during mid-day trading on Tuesday, reaching $9.40. The stock had a trading volume of 299,421 shares, compared to its average volume of 172,110. The company has a current ratio of 7.61, a quick ratio of 7.47 and a debt-to-equity ratio of 2.83. Corium International has a 1-year low of $7.17 and a 1-year high of $13.93.

In other Corium International news, VP Parminder Singh sold 3,133 shares of the firm’s stock in a transaction dated Friday, August 17th. The shares were sold at an average price of $9.01, for a total value of $28,228.33. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Peter D. Staple sold 76,341 shares of the firm’s stock in a transaction dated Friday, August 17th. The stock was sold at an average price of $8.81, for a total transaction of $672,564.21. Following the completion of the transaction, the chief executive officer now directly owns 362,316 shares in the company, valued at approximately $3,192,003.96. The disclosure for this sale can be found here. Insiders sold 119,965 shares of company stock worth $1,060,275 in the last three months. 30.80% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of CORI. Franklin Resources Inc. raised its holdings in shares of Corium International by 115.3% during the first quarter. Franklin Resources Inc. now owns 2,059,175 shares of the biopharmaceutical company’s stock valued at $23,618,000 after buying an additional 1,102,910 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Corium International by 17.8% during the second quarter. BlackRock Inc. now owns 2,215,762 shares of the biopharmaceutical company’s stock valued at $17,748,000 after buying an additional 335,257 shares during the last quarter. Royce & Associates LP raised its holdings in shares of Corium International by 99.2% during the second quarter. Royce & Associates LP now owns 502,564 shares of the biopharmaceutical company’s stock valued at $4,026,000 after buying an additional 250,300 shares during the last quarter. Candriam Luxembourg S.C.A. raised its holdings in shares of Corium International by 127.9% during the first quarter. Candriam Luxembourg S.C.A. now owns 196,000 shares of the biopharmaceutical company’s stock valued at $2,248,000 after buying an additional 110,000 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Corium International by 1,746.7% during the first quarter. JPMorgan Chase & Co. now owns 96,935 shares of the biopharmaceutical company’s stock valued at $1,112,000 after buying an additional 91,686 shares during the last quarter.

About Corium International

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Featured Story: What is a put option?

Get a free copy of the Zacks research report on Corium International (CORI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.